RNAi inhibition of alpha-ENaC expression

1. A composition comprising an iRNA agent to alpha-ENaC, comprising a sense strand and an antisense strand, wherein:

the sequence of the sense strand is the sequence of SEQ ID NO: 1297 or nucleotides 1-19 of SEQ ID NO: 1297,

and the sequence of the antisense strand is the sequence of SEQ ID NO: 1298 or nucleotides 1-19 of SEQ ID NO: 1298,

wherein the sense and/or antisense strand are modified or unmodified.

2. The composition of claim 1 , wherein the iRNA agent comprises a modification that causes the iRNA agent to have increased stability in a biological sample.

3. The composition of claim 1 , wherein the iRNA agent comprises at least one phosphorothioate or a 2′-modified nucleotide.

4. The composition of claim 1 , wherein the iRNA agent comprises:

at least one 5′-uridine-guanine-3′(5′-ug-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide;

at least one 5′-cytidine-adenine-3′(5′-ca-3′) dinucleotide, wherein the 5′-cytidine is a 2′-modified nucleotide; and/or

at least one 5′-uridine-uridine-3′(5′-uu-3′) dinucleotide, wherein the 5′-uridine is a 2′-modified nucleotide.

5. The composition of claim 1 , wherein the iRNA agent comprises a 2′-modification selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O—N-methylacetamido (2′-O-NMA).

6. The composition of claim 1 , wherein the iRNA agent comprises a blunt end.

7. The composition of claim 1 , wherein the iRNA agent comprises a nucleotide overhang having 1 to 4 unpaired nucleotides.

8. The composition of claim 1 , wherein the iRNA agent comprises a nucleotide overhang at the 3′-end of the antisense strand of the iRNA agent.

9. A composition comprising an iRNA agent to alpha-ENaC, comprising a sense strand and an antisense strand, wherein: the sequence of the sense strand is the sequence of SEQ ID NO: 1297, and the sequence of the antisense strand is the sequence of SEQ ID NO: 1298.

10. The composition of claim 1 , wherein the iRNA agent is ligated to one or more diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, Oligo Lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.

11. A method of treating a human subject having a pathological state mediated at least in part by alpha-ENaC expression, the method comprising the step of administering to the subject a therapeutically effective amount of a composition of claim 1 .

12. The method of claim 11 , wherein the pathological state is cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma, respiratory tract infections, lung carcinoma, Liddles syndrome, hypertension, renal insufficiency, and/or electrolyte imbalance.

13. A composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises a first strand and a second strand, wherein the sequence of the first strand is the sequence of SEQ ID NO: 1297 or nucleotides 1-19 of SEQ ID NO: 1297, and the sequence of the second strand is the sequence of SEQ ID NO: 1298 or nucleotides 1-19 of SEQ ID NO: 1298.

14. A method of treating a human subject having a pathological state mediated at least in part by alpha-ENaC expression, the method comprising the step of administering to the subject a therapeutically effective amount of a composition of claim 9 .

15. The method of claim 14 , wherein the pathological state is cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma, respiratory tract infections, lung carcinoma, Liddles syndrome, hypertension, renal insufficiency, and/or electrolyte imbalance.

16. A method of treating a human subject having a pathological state mediated at least in part by alpha-ENaC expression, the method comprising the step of administering a therapeutically effective amount of a composition comprising an iRNA agent to alpha-ENaC, comprises a first strand and a second strand, wherein:

the sequence of the sense strand is the sequence of SEQ ID NO: 1297 or nucleotides 1-19 of SEQ ID NO: 1297,

and the sequence of the antisense strand is the sequence of SEQ ID NO: 1298 or nucleotides 1-19 of SEQ ID NO: 1298,

wherein the sense and/or antisense strand are modified or unmodified .

17. The method of claim 16 , wherein the composition is administered in an amount sufficient to reduce the level of alpha-ENaC expression in a cell or tissue of the subject.

18. The method of claim 16 , wherein the pathological state is cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease (COPD), asthma, respiratory tract infections, lung carcinoma, Liddles syndrome, hypertension, renal insufficiency, and/or electrolyte imbalance.

19. The composition of claim 1 , wherein the iRNA agent inhibits at least 90% of alpha-ENaC expression at 50 nM in H441 cells in vitro.

20. The composition of claim 1 , wherein the first and/or second strand of the iRNA agent comprise a terminal TsT.